Statin use is associated with carotid plaque composition: The Rotterdam Study

Blerim Mujaj a, Daniel Bos a,b,e, Mariana Selwaness b, Maarten J.G. Leening a,c,e, Maryam Kavousi a, Jolanda J. Wentzel d, Aad van der Lugt b, Albert Hofman c, Bruno H. Stricker a,e, Meike W. Vernooij a,b, Oscar H. Franco a

a Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands
b Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
c Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands
d Department of Biomechanics, Erasmus MC, Rotterdam, The Netherlands
e Department of Clinical Epidemiology, Harvard TH Chan School of Public Health, Boston, USA

ARTICLE INFO

Article history:
Received 22 June 2017
Received in revised form 1 February 2018
Accepted 26 February 2018
Available online xxxx

Keywords:
Carotid artery
Statin
Plaque composition
MRI
Atherosclerosis
Epidemiology

ABSTRACT

Background: Statins represent a key treatment for cardiovascular disease. Nevertheless, the direct effects of statin treatment on the composition of atherosclerotic plaques remain elusive.

Objectives: We aimed to investigate the association of statin treatment with the presence of different plaque components located in the carotid arteries within a population-based setting.

Methods: From the population-based Rotterdam Study, 1740 participants with carotid atherosclerosis (mean age 72.9 years, 46% women) underwent MRI of the carotid arteries to determine the presence of calcification, lipid core, and intraplaque hemorrhage. Information for the duration and dosage of statin use was obtained from pharmacy records for all participants. We used logistic regression models to study the association of statin use with the presence of plaque components.

Results: Statin treatment was associated with a higher presence of calcification (OR: 1.73 [95% CI: 1.22–2.44]). Longer duration of use strengthened this association (OR: 1.82 [95% CI: 1.00–3.33] for 10 to 48 months, and OR 1.74 [95% CI: 1.09–2.77] for >48 months, compared to OR: 1.65 [95% CI: 0.94–2.89] for ≤10 months). Current statin treatment was also associated with a lower presence of lipid core (OR: 0.66 [95% CI: 0.42–1.04]), but only when using statins for 10 months or less. Any dosage of statins was associated with a higher presence of calcification, whilst only high dosages (DDD ≥ 1333) were associated with a lower presence of lipid core.

Conclusions: Active, high-dosage statin use seems to beneficially influence the composition of carotid atherosclerosis by shifting the composition from vulnerable plaque with a lipid core to more stable calcified plaque.

© 2017 Published by Elsevier B.V.

1. Introduction

Atherosclerosis in the carotid artery is the most important cause of stroke [1–3]. Within the complex etiological framework of atherosclerosis, a key role is played by serum low-density lipoprotein (LDL) cholesterol, specifically in the initiation and progression of the disease [2]. Following this, lowering the concentration of LDL cholesterol using statins has become a cornerstone for primary prevention of stroke and cardiovascular events overall [4,5].

Several trials have demonstrated a direct effect of statins on the formation of coronary artery disease and a lower risk of coronary events [6–8]. This direct effect of statins is thought to be due to the beneficial influence of statins on plaque stability by increasing the amount of calcium at the cost of vulnerable plaque components such as lipid core [9].

In contrast to the extensive research in the field of the coronary arteries, studies on the effects of statin treatment on atherosclerosis in the carotid arteries are far more limited, especially from a general-population perspective. Yet, especially in light of the increased risk of stroke that carotid atherosclerosis harbors [10], it is paramount to also disentangle the effect of statin treatment on carotid artery atherosclerosis. Moreover, it is important to highlight that findings regarding the physiopathology of coronary artery disease may not be directly generalizable to the carotid arteries, given that correlation for atherosclerosis across vessel beds is only moderate [11,12]. Magnetic resonance imaging (MRI) allows detailed characterization of different plaque components, including lipid core, intraplaque hemorrhage (IPH), and calcification [13,14].

Please cite this article as: B. Mujaj, et al., Statin use is associated with carotid plaque composition: The Rotterdam Study, Int J Cardiol (2017), https://doi.org/10.1016/j.ijcard.2018.02.111
Against this background, we investigated the association of statin use with specific components of the carotid plaque in a large population-based sample of persons with subclinical atherosclerosis.

2. Methods

2.1. Setting

The current study is embedded within The Rotterdam Study, a prospective population-based cohort study, in participants of 2455 living in Ommoord, a district of Rotterdam [15]. The Rotterdam Study has been approved by the medical ethics committee, according to the Population Screening Act; Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of the Netherlands. All participants provided written informed consent.

2.2. Study population

Participants were selected on the basis of a carotid artery ultrasound examination (intima–media thickness = 2.5 mm in one or both carotid arteries) which is performed in all participants of the Rotterdam Study. Between the years 2007 and 2012, 2666 participants were invited to undergo an MRI examination of the carotid arteries. From the invited participants, 684 participants did not undergo MRI scanning due to claustrophobia (n = 57), physical limitations (n = 191), MRI contraindications (n = 115), refused to participate (n = 19), and no-show or lost to follow-up (n = 49), leaving 1982 participants. From these, we excluded another 242 participants due to poor image quality (n = 95), scan interruption due to claustrophobia (n = 106) and absence of plaque bilaterally (n = 41), leaving 1740 participants in the present analyses.

2.3. Carotid scanning and analysis of plaque components

MRI imaging was performed using a 1.5 Tesla scanner (GE Healthcare, Milwaukee, WI, USA) with a dedicated bilateral phased-array surface coil (Machnet, Eelde, the Netherlands). A standardized scanning protocol was used with a total scanning time of approximately 30 min. The protocol included 4 sequences in axial plane: a proton density weighted (PDW)-fast spin echo (FSE)-black blood (BB) sequence (in-plane resolution 130/160 × 130/128 = 0.8 × 1 cm); a PDW-FSE-BB with an increased in-plane resolution (in-plane resolution 130/224 × 130/160 = 0.5 × 0.8 cm); a PDW-echo planar imaging (EPI) sequence (in-plane resolution 130/160 × 70/160 = 0.8 × 0.4 cm); and two three-dimensional (3D) sequences: a 3D-T1 weighted (T1w)-gradient echo sequence (in-plane resolution 180/192 × 180/180 = 0.9 × 1 cm, and a 3D phased-contrast magnetic resonance angiography (3D-PC-MRA) (in-plane resolution 180/256 × 180/128 = 0.7 × 1.4 cm). Details of the scan protocol, scan reading procedure, and reproducibility are described in detail elsewhere [16]. We assessed plaque characteristics with a maximum thickness of ≤2.5 mm on MRI. On the proton density weighted fast spin echo images, maximum carotid wall thickness was measured, and degree of luminal stenosis was calculated using the North American Symptomatic Carotid Endarterectomy Trial criteria [17]. The carotid images were evaluated for the presence of three different plaque components: calciﬁcation, lipid core, and IPH. Calcium was deﬁned as the presence of a hypointense region in the plaque on all sequences [18–20]. IPH was deﬁned as the presence of a hyperintense region in the atherosclerotic plaque on 3D-T1w-GRE [21,22]. Lipid core presence was deﬁned as a hypointense region, not classiﬁed as IPH or calcification, in the plaque on PDW-FSE, PDW-EPI and T2w-EPI sequences, and with respect to the signal intensity drop on the T2w-EPI sequence [18,19,23]. All sequences were the result of use (prescription episode) was calculated by dividing the number of dispensed tablets by the prescribed daily number. On the date of carotid MRI scanning, every participant was classiﬁed into one of the following mutually exclusive categories: "current use" if the measurement occurred within a prescription episode; "past use" if the participant had previously stopped using statins; or "never use" if the participant had not used statins during the study period. Next, we created tertiles of the duration of cumulative exposure to statins among statin users. This resulted in the following categories: current use ≤10 months; current use 10–48 months; current use >48 months; past use ≤10 months; past use 10–48 months and past use >48 months since the end of the last prescription episode. To facilitate direct dose comparisons between drugs from the same therapeutic drug group, the daily deﬁned dose (DDD) of statin therapy was expressed [24]. Finally, we created tertiles of discontinuation of statin use among past users as follows: 3 months, 1–16 months and >16 months.

2.5. Other measurements in the Rotterdam Study

Information on other relevant measurements was obtained by interview, physical examination, and blood sampling [15]. Smoking status was categorized into never, the past, and current smoking. Diabetes mellitus was deﬁned as fasting blood glucose ≥6.9 mmol/L, nonfasting glucose ≥11.0 mmol/L, or use of glucose-lowering medication. Systolic and diastolic blood pressure was measured using a random-zero sphygmomanometer on the right arm. Two measurements were performed and the average of the two was used in the analyses. Body mass index (BMI) was calculated based on weight in kilograms divided by height in meters squared. Serum total cholesterol and high-density lipoprotein (HDL) levels were measured using standard laboratory techniques. The use of antihypertensive medication and vitamin K antagonists (VKA) was obtained from pharmacy records [15].

2.6. Statistical analysis

We used a three-step statistical analysis approach to investigate the association between statin use and the presence of different plaque components. First, we used two logistic regression models to assess the association of statin use (never, former, current) with the presence of calcification, lipid core, and IPH in any of the two carotid arteries. In the ﬁrst model, we adjusted these analyses for age and sex. In the second model, we additionally adjusted for smoking, diabetes mellitus, systolic blood pressure, diastolic blood pressure, BMI, total cholesterol, HDL, use of antihypertensive medication, and use of vitamin K antagonists. Factors were selected based on previous literature and univariate analyses. Vitamin K antagonists were handled as a potential confounder given that these accelerate the deposition of calcium in the arterial wall through the competitive lowering of vitamin K receptor binding. Second, we investigated whether the duration of statin use was associated with any of the three plaque components, using the same regression models. For the duration of statin use, we compared the six categories as deﬁned above (based on tertiles of use), vs. never use. Third, we investigated whether the DDD of statin treatment was associated with any of the three plaque components. Fourth, we created tertiles of DDD of statin treatment and compared the three tertile categories with never use. Finally, we investigated the association of discontinuation of statin use with plaque composition (based on tertiles of discontinuation).

Additionally, we performed sensitivity analyses to address confounding by indication. We re-analyzed all associations in participants without prevalent cardiovascular diseases (participants with a conﬁrmed history of stroke, myocardial infarction, and coronary heart disease). (Table 1) [45,6]. Finally, we performed stratiﬁed analyses for age below and above 70 years of age and sex, to investigate whether associations differed by these age groups.

Table 1

Baseline characteristics of the study population (n = 1740).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Never user N = 1014</th>
<th>Current user N = 526</th>
<th>Past user N = 200</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>72.05 ± 9.9</td>
<td>73.60 ± 8.0</td>
<td>75.44 ± 6.8</td>
</tr>
<tr>
<td>Gender (women [%])</td>
<td>48.8</td>
<td>38.2</td>
<td>52.0</td>
</tr>
<tr>
<td>Current smoking [%]</td>
<td>30.8</td>
<td>33.5</td>
<td>30.0</td>
</tr>
<tr>
<td>Diabetes mellitus [%]</td>
<td>8.2</td>
<td>24.0</td>
<td>21.0</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>144.6 ± 20</td>
<td>146.1 ± 21</td>
<td>148.4 ± 20</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>80.7 ± 10</td>
<td>79.2 ± 10</td>
<td>80.1 ± 12</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.0 ± 3.6</td>
<td>27.6 ± 3.2</td>
<td>27.9 ± 3.7</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>5.83 ± 0.8</td>
<td>5.22 ± 1.1</td>
<td>5.65 ± 1.1</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>1.46 ± 0.3</td>
<td>1.29 ± 0.3</td>
<td>1.37 ± 0.3</td>
</tr>
<tr>
<td>Antihypertensive medication use [%]</td>
<td>27.4</td>
<td>59.1</td>
<td>47.5</td>
</tr>
<tr>
<td>Vitamin K antagonists use [%]</td>
<td>4.2</td>
<td>8.4</td>
<td>5.0</td>
</tr>
<tr>
<td>History of stroke [%]</td>
<td>2.5</td>
<td>12.0</td>
<td>10.5</td>
</tr>
<tr>
<td>History of myocardial infarction [%]</td>
<td>1.9</td>
<td>21.5</td>
<td>20.0</td>
</tr>
<tr>
<td>History of CHD [%]</td>
<td>1.4</td>
<td>26.8</td>
<td>22.0</td>
</tr>
<tr>
<td>Degree of stenosis [%]</td>
<td>16.1 ± 17.5</td>
<td>22.3 ± 23.9</td>
<td>20.4 ± 21.4</td>
</tr>
<tr>
<td>Wall thickness, mm</td>
<td>3.1 ± 0.6</td>
<td>3.3 ± 0.7</td>
<td>3.3 ± 0.8</td>
</tr>
<tr>
<td>Presence of calcification</td>
<td>78.7</td>
<td>88.4</td>
<td>84.5</td>
</tr>
<tr>
<td>Presence of lipid core</td>
<td>45.0</td>
<td>42.4</td>
<td>43.5</td>
</tr>
<tr>
<td>Presence of IPH</td>
<td>30.7</td>
<td>39.5</td>
<td>42.0</td>
</tr>
</tbody>
</table>

Values are means with standard deviations for continuous variables and percentages for dichotomous or categorical variables.

Abbreviations: BMI = body mass index, CHD = coronary heart disease, HDL = high-density lipoprotein.
دریافت فوری متن کامل مقاله

امکان دانلود نسخه تمام متن مقالات انگلیسی
امکان دانلود نسخه ترجمه شده مقالات
پذیرش سفارش ترجمه تخصصی
امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
امکان دانلود رایگان ۲ صفحه اول هر مقاله
امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
دانلود فوری مقاله پس از پرداخت آنلاین
پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات